Jiangsu Hengrui Medicine
600276.SS
#439
Rank
NZ$75.71 B
Marketcap
$11.87
Share price
0.00%
Change (1 day)
13.49%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): NZ$1.66 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are NZ$3.88 Billion. , an increase over its 2023 earnings that were of NZ$1.18 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 NZ$1.77 B50.69%
2023 NZ$1.18 B11.4%
2022 NZ$1.05 B-13.65%
2021 NZ$1.22 B-34.21%
2020 NZ$1.86 B15.95%
2019 NZ$1.60 B33.03%
2018 NZ$1.20 B20.89%
2017 NZ$0.99 B23.89%
2016 NZ$0.80 B11.21%
2015 NZ$0.72 B39.5%
2014 NZ$0.52 B20.61%
2013 NZ$0.43 B11.46%
2012 NZ$0.38 B29.7%
2011 NZ$0.29 B31.16%
2010 NZ$0.22 B27.92%
2009 NZ$0.17 B5.8%
2008 NZ$0.16 B79.95%
2007 NZ$93.42 M32.89%
2006 NZ$70.3 M38.19%
2005 NZ$50.87 M21.56%
2004 NZ$41.85 M13.95%
2003 NZ$36.73 M38.06%
2002 NZ$26.6 M